Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 16.42 EUR -0.24%
Market Cap: 543m EUR

EV/EBITDA
Enterprise Value to EBITDA

-31.3
Current
-13.6
Median
12.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-31.3
=
Enterprise Value
557.5m EUR
/
EBITDA
-17.8m EUR
Market Cap EV/EBITDA
FR
Medincell SA
PAR:MEDCL
544.3m EUR -31.3
US
Eli Lilly and Co
NYSE:LLY
744B USD 36
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
362.6B USD 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 14.3
CH
Roche Holding AG
SIX:ROG
205.8B CHF 9.3
CH
Novartis AG
SIX:NOVN
186.3B CHF 10.4
UK
AstraZeneca PLC
LSE:AZN
163.3B GBP 130.8
US
Merck & Co Inc
NYSE:MRK
199.5B USD 8.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
135.8B USD 7.4
EBITDA Growth EV/EBITDA to Growth
FR
Medincell SA
PAR:MEDCL
Average EV/EBITDA: 433.7
Negative Multiple: -31.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
hidden
2-Years Forward
EV/EBITDA
hidden
3-Years Forward
EV/EBITDA
hidden